Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors

Published:2015-10-01 Issue:14 Volume:126 Page:1699-1706
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Wang Wei¹,Cortes Jorge E.²,Lin Pei¹,Beaty Michael W.³,Ai Di¹,Amin Hesham M.¹,McDonnell Timothy J.¹,Ok Chi Young¹,Kantarjian Hagop M.²,Medeiros L. Jeffrey¹,Hu Shimin¹

Affiliation:

1. Department of Hematopathology and

2. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX; and

3. Department of Pathology, Wake Forest Baptist Health, Winston-Salem, NC

Abstract

Key Points The emergence of 3q26.2 rearrangements in CML is associated with resistance to TKI treatment and poor prognosis. 3q26.2 rearrangements play a predominant role in determining prognosis, irrelevant to the presence or absence of other additional chromosomal abnormalities in CML.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/126/14/1699/1389014/1699.pdf

Reference40 articles.

1. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.;Daley;Science,1990

2. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.;Rowley;Nature,1973

3. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.;Fabarius;Blood,2011

4. How I treat CML blast crisis.;Hehlmann;Blood,2012

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A molecularly-confirmed extraskeletal myxoid chondrosarcoma with dual gene rearrangements, EWSR1::NR4A3 and HAPLN1::EDIL3 fusion;Human Pathology Reports;2024-09

2. Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia;International Journal of Hematology;2024-05-15

3. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-02

4. Accelerated-phase CML: de novo and transformed;Hematology;2023-12-08

5. The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on tyrosine kinase inhibitor therapy predicts the imatinib treatment failure;Leukemia Research;2023-09